These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 24188045)
1. Protective immunity against malaria after vaccination. de Souza JB Parasite Immunol; 2014 Mar; 36(3):131-9. PubMed ID: 24188045 [TBL] [Abstract][Full Text] [Related]
2. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Cockburn IA; Seder RA Nat Immunol; 2018 Nov; 19(11):1199-1211. PubMed ID: 30333613 [TBL] [Abstract][Full Text] [Related]
3. Understanding protective immune mechanisms induced by malaria vaccines in the context of clinical trials. Dobaño C; Campo JJ Hum Vaccin; 2009 Aug; 5(8):562-5. PubMed ID: 19287202 [TBL] [Abstract][Full Text] [Related]
4. The potential for recruiting immune responses toward type 1 or type 2 T cell help. Golding B; Zaitseva M; Golding H Am J Trop Med Hyg; 1994; 50(4 Suppl):33-40. PubMed ID: 8172330 [TBL] [Abstract][Full Text] [Related]
5. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria. Rainczuk A; Scorza T; Spithill TW; Smooker PM Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453 [TBL] [Abstract][Full Text] [Related]
6. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Bergmann-Leitner ES; Legler PM; Savranskaya T; Ockenhouse CF; Angov E Vaccine; 2011 Aug; 29(35):5940-9. PubMed ID: 21722682 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Friesen J; Matuschewski K Vaccine; 2011 Sep; 29(40):7002-8. PubMed ID: 21787828 [TBL] [Abstract][Full Text] [Related]
11. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Burns JM; Flaherty PR; Nanavati P; Weidanz WP Infect Immun; 2004 Oct; 72(10):5605-12. PubMed ID: 15385457 [TBL] [Abstract][Full Text] [Related]
12. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Reyes-Sandoval A; Sridhar S; Berthoud T; Moore AC; Harty JT; Gilbert SC; Gao G; Ertl HC; Wilson JC; Hill AV Eur J Immunol; 2008 Mar; 38(3):732-41. PubMed ID: 18266272 [TBL] [Abstract][Full Text] [Related]
13. Malaria vaccines in the eradication era: current status and future perspectives. Wilson KL; Flanagan KL; Prakash MD; Plebanski M Expert Rev Vaccines; 2019 Feb; 18(2):133-151. PubMed ID: 30601095 [TBL] [Abstract][Full Text] [Related]
14. Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force. Tyagi RK; Garg NK; Sahu T J Control Release; 2012 Aug; 162(1):242-54. PubMed ID: 22564369 [TBL] [Abstract][Full Text] [Related]